The effect of initial antidepressant type on treatment adherence in outpatients with new onset depression

Ji, Nam-Ju; Jeon, Seung-Yeon; Min, Kyung-Joon; Ki, Mi Ran; Lee, Weon-Young

doi:10.1016/j.jad.2022.05.011

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 Cumulative meta-analysis of studies ordered by year of publication to 770 determinants of adherence have been described in previous literature [84], only a few could be explored in this review. Although the prescribed antidepressant treatment has been shown to be a predictor of adherence [85,86], most included studies did not report the specific antidepressant medicines that patients receive (Table 1). Moreover, there were studies that did not specify the patient´s phase of adherence, some of them because they were published before the publication of Vrijens et al taxonomy [5].…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of interventions to improve medication adherence in adults with depressive disorders: a meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background Non-adherence to medication is a major obstacle in the treatment of depressive disorders. We systematically reviewed the literature to evaluate the effectiveness of interventions aimed at improving adherence to medication among adults with depressive disorders with emphasis on initiation and implementation phase. Methods We searched Medline, EMBASE, The Cochrane Central Register of Controlled Trials (CENTRAL), PsycINFO, Social Science Citation Index and Science Citation Index for randomized or non-randomized controlled trials up to January 2022. Risk of bias was assessed using the criteria of the Cochrane Collaboration. Meta-analyses, cumulative and meta-regression analyses for adherence were conducted. Results Forty-six trials (n = 24,324) were included. Pooled estimate indicates an increase in the probability of adherence to antidepressants at 6 months with the different types of interventions (OR 1.33; 95% CI: 1.09 to 1.62). The improvement in adherence is obtained from 3 months (OR 1.62, 95% CI: 1.25 to 2.10) but it is attenuated at 12 months (OR 1.25, 95% CI: 1.02 to 1.53). Selected articles show methodological differences, mainly the diversity of both the severity of the depressive disorder and intervention procedures. In the samples of these studies, patients with depression and anxiety seem to benefit most from intervention (OR 2.77, 95% CI: 1.74 to 4.42) and collaborative care is the most effective intervention to improve adherence (OR 1.88, 95% CI: 1.40 to 2.54). Conclusions Our findings indicate that interventions aimed at improving adherence to medication among adults with depressive disorders are effective up to six months. However, the evidence on the effectiveness of long-term adherence is insufficient and supports the need for further research efforts. Trial registration International Prospective Register for Systematic Reviews (PROSPERO) number: CRD42017065723.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of interventions to improve medication adherence in adults with depressive disorders: a meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Although the reuptake inhibitor drug fluoxetine boasts exceptional safety and tolerance, it remains the foremost first-line antidepressant in clinical practice [5]. Nevertheless, as we entered the new century, antidepressant drugs encountered significant challenges, including low patient compliance and elevated relapse rates, coupled with a sluggish pace in the development of new medications [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

Nerolidol reduces depression-like behavior in mice and suppresses microglia activation by down-regulating DNA methyltransferase 1

Zhang,

Zhou,

Feng

et al. 2024

NeuroReport

View full text Add to dashboard Cite

Modern medicine has unveiled that essential oil made from Aquilaria possesses sedative and hypnotic effects. Among the chemical components in Aquilaria, nerolidol, a natural sesquiterpene alcohol, has shown promising effects. This study aimed to unravel the potential of nerolidol in treating depression. Chronic unpredictable mild stress (CUMS) was utilized to induce depression-like behavior in mice, and open field test, sucrose preference, and tail suspension test was conducted. The impacts of nerolidol on the inflammatory response, microglial activation, and DNA methyltransferase 1 (DNMT1) were assessed. To study the regulatory role of DNMT1, lipopolysaccharide (LPS) was used to treat BV2 cells, followed by the evaluation of cell viability and DNMT1 level. Additionally, the influence of DNMT1 overexpression on BV2 cell activation was determined. Behavioral analysis revealed that nerolidol reduced depression-like behavior in mice. Nerolidol reduced the levels of inflammatory factors and microglial activation caused by CUMS. Nerolidol treatment was found to reduce DNMT1 levels in mouse brain tissue and it also decrease the LPS-induced increase in DNMT1 levels in BV2 cells. DNMT1 overexpression reversed the impacts of nerolidol on the inflammation response and cell activation. This study underscores the potential of nerolidol in reducing CUMS-induced depressive-like behavior and inhibiting microglial activation by downregulating DNMT1. These findings offer valuable insights into the potential of nerolidol as a therapeutic option for depression.

show abstract

Superando las barreras en el abordaje del paciente crónico

Molinera¹,

Garrote²,

Rodríguez³

et al. 2023

Medicina de Familia. SEMERGEN

View full text Add to dashboard Cite

The effect of initial antidepressant type on treatment adherence in outpatients with new onset depression

Cited by 3 publications

References 20 publications

Effectiveness of interventions to improve medication adherence in adults with depressive disorders: a meta-analysis

Effectiveness of interventions to improve medication adherence in adults with depressive disorders: a meta-analysis

Nerolidol reduces depression-like behavior in mice and suppresses microglia activation by down-regulating DNA methyltransferase 1

Superando las barreras en el abordaje del paciente crónico

Contact Info

Product

Resources

About